Evidence map›Paper›PMID 41400007›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Thyroid function and cognitive health: rethinking the relationship between "suboptimal" TSH/FT4 levels and cognitive decline.

Dvir Dori, Bruna Seixas-Lima, Carlos Roncero, Durjoy Lahiri, Michael Borrie, Howard Chertkow

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dvir DoriBaycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada.ORCID 0009-0004-5332-3636
Bruna Seixas-LimaBaycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada.
Carlos RonceroBaycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada.
Durjoy LahiriBaycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada.
Michael BorrieParkwood Institute, Geriatric Medicine, Department of Medicine, Western University, London, Ontario, Canada.
Howard ChertkowBaycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada.ORCID 0000-0003-3749-8132

Funding

the Canadian Institutes of Health Research BDO-148341the Canadian Institutes of Health Research CNA-137794the Canadian Institutes of Health Research CNA-163902
6 · The paper itself

Abstract

introductionControversial hypotheses suggest that "suboptimal" thyroid function - defined as higher-normal thyroid-stimulating hormone (TSH) (2.0 to 4.5 μIU/mL) or low-normal free thyroxine (FT4) - may increase risk of cognitive decline and dementia in older patients.

methodsWe examined this claim using data from the Canadian Comprehensive Assessment of Neurodegeneration and Dementia cohort (ages 50 to 91; cognitive statuses from unimpaired to dementia, rarer subtypes of dementia excluded). Thyroid function was categorized as "optimal" (TSH < 2.0 μIU/mL or FT4 ≥ 16.74 pmol/L) or "suboptimal." Six hundred eighty-eight participants had TSH data, and 476 participants had FT4 data.

resultsChi-squared analyses showed no significant association between "suboptimal" thyroid function and cognitive impairment (TSH: χ DISCUSSION: These findings do not support claims that higher-normal TSH or low-normal FT4 contribute to cognitive impairment. Caution is warranted against advocating unproven thyroid supplementation for cognitive health. HIGHLIGHTS: No link was found between "suboptimal" thyroid function and cognitive impairment. Higher-normal TSH levels do not indicate dementia risk or hypothyroidism. Among participants with elevated TSH, 98.6% had normal FT4 levels. Redefining TSH cutoffs to 2.0 μIU/mL lacks clinical justification. Findings question the functional medicine approach of thyroid supplementation for cognitive health.

Indexed as

CognitionCognitive DysfunctionThyroid GlandThyrotropinThyroxineAgedAged, 80 and overCanadaCohort StudiesFemaleHumansHypothyroidismMaleMiddle AgedThyroid Function TestsThyrotropinThyroxineAlzheimer's diseasecognitiondementiafree thyroxine (FT4)thyroidTSH

Identifiers

PMID41400007
PMCPMC12706624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.